Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer

<p>Abstract</p> <p>Background</p> <p>Both paclitaxel (P) and carboplatin (C) have significant activity in non-small cell lung cancer (NSCLC). The weekly administration of P is active, dose intense, and has a favorable toxicity profile. We retrospectively reviewed the data of 51 consecutive patients...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Salepci Taflan, Ozkan Alper, Turken Orhan, Hatabay Nilgun F, Gumus Mahmut, Turhal Nazim S, Yumuk Perran F, Aliustaoglu Mehmet, Ahiskali Rengin
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2005-01-01
Serija:	BMC Cancer
Online dostop:	http://www.biomedcentral.com/1471-2407/5/10
Oznake:	Označite Brez oznak, prvi označite!